FLAMSA-busulfan-melphalan as sequential conditioning regimen in HLA-matched or haploidentical hematopoietic stem cell transplantation for high-risk myeloid diseases

Because of their inherent chemoresistance, relapsed/refractory (R/R) myeloid malignancies remain a therapeutic challenge. For patients with primary refractory acute myeloid leukemia (AML) treated with another course of chemotherapy, the median survival is less than 6 months, and the 1-year overall survival is under 20%1,2. Regarding high-risk myelodysplastic syndrome (MDS), standard therapies involve a hypomethylating agent, to be continued as long as the patient responds3. In case of failure, median survival is also less than 6 months4.

Source: Biology of Blood and Marrow Transplantation - July 27, 2021 Category: Hematology Authors: Ludovic Jondreville, Damien Roos-Weil, Madalina Uzunov, In ès Boussen, Adrien Grenier, Françoise Norol, Véronique Morel, Stéphanie Nguyen, Laetitia Souchet Source Type: research